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Direct oral anticoagulants (DOACs) have beenmarketed in theUnited States since 2010.While numerous large-
scale prospective phase 3 outcomes studies have documented the effectiveness of DOACs for the prevention of
stroke and systemic embolism in patients with nonvalvular atrial ﬁbrillation, the primary safety concern with all
of these drugs—as it is with the more established oral anticoagulant warfarin—is the risk of major bleeding.
Postmarketing surveillance studies (PMSS) provide the opportunity to evaluate the safety of these recently
approved drugs across a spectrum of patients that may be broader than those included in randomized controlled
trials. This review will summarize the safety ﬁndings of numerous recently performed, large-scale PMSS
evaluations, and consider the currently available evidence regarding the risks for bleeding in patients treated
with DOACs, in order to give providers and patients additional evidence regarding the safety of DOACs.
 2016 Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).  The American Journal of Medicine (2016) 129, S41-S46
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0.1016/j.amjmed.2016.06.004systemic embolism in patients with nonvalvular atrial
ﬁbrillation (NVAF).1 The oral direct factor Xa (FXa)
inhibitors rivaroxaban and apixaban were subsequently
approved for treatment and prevention of deep vein
thrombosis (DVT) and pulmonary embolism (PE)
(including in patients who have undergone hip or knee
replacement surgery) and for reduction in risk of stroke and
systemic embolism in patients with NVAF.2,3 Dabigatran
was also approved for treatment and prevention of DVT and
PE and for the prophylaxis of DVT and PE in patients who
have undergone hip replacement surgery.1 Additionally, the
FXa inhibitor edoxaban has been approved in the United
States to reduce the risk of stroke and systemic embolism in
patients with NVAF and for the treatment of DVT and PE.4
The primary safety concern with all of these drugs—as it
is with the older, more established oral anticoagulant
warfarin—is the risk of bleeding as a complication of
deliberate anticoagulation aimed at preventing pathologic
thrombosis. Although statistically rare, an intracranial
hemorrhage (ICH) is the most feared adverse event associ-
ated with all oral anticoagulants because of its devastating
clinical sequelae and high rate of mortality. Anticoagulant-
associated gastrointestinal hemorrhages are more common,
but are less often likely to be fatal adverse events.-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
S42 The American Journal of Medicine, Vol 129, No 11A, November 2016In recent years, researchers have reported the ﬁndings of
postmarketing surveillance studies (PMSS) of adverse
events associated with the DOACs. These studies followed
the publication of randomized controlled trials (RCTs) that
established the foundational evidence for the comparative
safety and efﬁcacy of DOACs vs warfarin and formed the
basis for FDA approval.5-7 Postmarketing surveillance may
take the form of independent studies, evaluations performed
by regulators, or as part of phase 4 research performed by
the drug manufacturers. These studies are observational in
nature. Postmarketing surveillance is typically conducted
in retrospect from large databases (eg, those maintained by
Medicare, the FDA Adverse Event Reporting System
[FAERS], private health-maintenance organizations, health
beneﬁts provider roles, health insurance company), or ob-
tained from ongoing prospective registries (eg, Global
Registry on Long-Term Oral Antithrombotic Treatment in
Patients with Atrial Fibrillation [GLORIA-AF]8 or Global
Anticoagulant Registry in the FIELD-Atrial Fibrillation
[GARFIELD]9 for patients with NVAF).
Postmarketing research, therefore, attempts to assess the
effectiveness and safety of the drug in a “real-world” setting
that is representative of how it is being prescribed and used in
clinical practice.10,11 The most common methodology in
these studies utilizes International Classiﬁcation of Diseases
(ICD) coding data to identify patients, determine baseline
demographics and clinical characteristics, and assess out-
comes or parameters of interest. The positive predictive value
of using ICD-9 and ICD-10 codes for identiﬁcation of
patients with strokes has been validated at 80% to 97%.12,13
Validation studies have also demonstrated good positive
predictive values with these codes for identifying the
presence and location of GI bleeding.14 Because ICD-10 for
inpatient hospital procedures was recently adopted in the
United States, published studies are based on ICD-9 coding.
Study cohorts in PMSS are not randomized, but
researchers may control for differences in patient character-
istics by using multivariable modeling or propensity score
matching. Observational research, such as PMSS, has
inherent limitations because of its uncontrolled, non-
randomized nature. The compared populations are potentially
subject to confounding factors that may have been excluded
in RCTs. Modeling or propensity score matching can reduce
or eliminate these factors, but some residual confounding
variables may remain. As a consequence of potential for bias,
the assessment of effectiveness—while performed and re-
ported—should be interpreted with caution.
These studies may consider treatment in larger and more
variable populations over greater periods of time than would
be feasible in a phase 3 RCT, and thus have the potential to
reveal more rare adverse events or provide more information
about anticipated adverse event rates. Postmarketing
research may also provide information on parameters that
RCTs are unable to evaluate due to ethical considerations
(eg, time delay to treatment or the management of rare
intentional overdoses). In addition, PMSS can provide
information about the treatment of patients who would beexcluded from RCTs or complex therapeutic scenarios
(eg, multiple conﬂicting comorbidities, extremes of age/body
habitus, or lifestyle consequences related to complications
of the drug in question).PUBLISHED STUDIES
Dabigatran
As the ﬁrst FDA-approved DOAC, dabigatran has been the
most frequent subject of PMSS (a PubMed literature search
in October 2015 found 21 completed observational studies
with dabigatran and 10 with rivaroxaban) in this therapeutic
area. Since the drug was introduced in 2010, several
observational studies have provided insights into the risk of
bleeding in patients treated with dabigatran vs the vitamin K
antagonist (VKA) warfarin (Table).1,5-7,15-20 The ﬁndings
of these studies have been broadly consistent with the results
of the Randomized Evaluation of Long-term anticoagulation
therapY (RE-LY) trial, which compared dabigatran with
warfarin in patients with NVAF.5
To date, the U.S. Medicare study reported by Graham et al1
evaluated the largest cohort of patients taking dabigatran.
These researchers compared bleeding risk in a propensity score
matching population of patientswithNVAFwhowere naïve to
anticoagulation and were prescribed either warfarin or dabi-
gatran etexilate (n ¼ 67,207 in each group). In the Medicare
cohort, the risk for major bleeding with dabigatran was similar
to warfarin (adjusted hazard ratio [HR] 0.97; 95% conﬁdence
interval [CI], 0.88-1.07). Risk for ICH was signiﬁcantly
reducedwith dabigatran (HR0.34; 95%CI, 0.26-0.46), but risk
for major GI bleeding was increased (HR 1.28; 95% CI, 1.14-
1.44). The risk of GI bleeding was highest in women aged 75-
84 years (HR 1.50; 95%CI, 1.20-1.88) and inmen andwomen
85 years (HR 1.55; 95% CI, 1.04-2.32) and (HR 2.18; 95%
CI, 1.61-2.97), respectively. Therewas no difference in the rate
of acute myocardial infarction between the groups (HR 0.92;
95% CI, 0.78-1.08).
Several additional studies assessed safety outcomes of
dabigatran as compared with warfarin users among patients
with NVAF in the U.S. Department of Defense database,3 in 2
privately administered U.S. patient databases,16 and in a
Danish national database (Table).17,21 These studies reported
similar ﬁndings as compared with the Medicare analysis,
extending PMSS data to non-Medicare patient cohorts. These
authors also found no increased risk of myocardial infarction
among dabigatran users vs patients taking warfarin. In addi-
tion to these studies, researchers for the FDA published a
postmarketing bleed comparison using data from the FAERS
for the ﬁrst year that dabigatran was available.22 Their data
showed that despite initial concerns about bleeding adverse
events with dabigatran, incidence rates were not higher than
concurrent incidence rates with warfarin.Rivaroxaban
Postmarketing data for the FXa inhibitors (rivaroxaban and
apixaban) have also been published. Two noncomparative
Table Bleeding and Myocardial Infarction Risk with DOACs vs Warfarin Given for Stroke Prevention in Atrial Fibrillation in RCTs and Large-Scale Observational Studies (Hazard Ratios and
Relative Risks are Adjusted Unless Indicated)
Study Mean Age Follow-Up Adjustment
Major Bleeding
Risk (95% CI)
Intracranial
Bleeding
Risk (95% CI)
GI Bleeding
Risk (95% CI)
Myocardial Infarction
Risk (95% CI)
Dabigatran etexilate
RE-LY5,* (150 mg BID) 71 y Median 2.0 y Cox proportional-
hazards models
RR 0.93 (0.81-1.07) RR 0.40 (0.27-0.60) RR 1.50 (1.19-1.89) RR 1.38 (1.00-1.91)
U.S. Medicare1
(75 mg and 150 mg)
>65 y Total 37,587
patient-years
PSM HR 0.97 (0.88-1.07) HR 0.34 (0.26-0.46) HR 1.28 (1.14-1.44) HR 0.92 (0.78-1.08)
U.S. Department
of Defense15 (75 mg and
150 mg)
74 y Mean 297  259 d PSM HR 0.87 (0.74-1.03) Unadjusted HR 0.49†
(0.30-0.79)
Unadjusted HR 1.13†
(0.94-1.37)
Unadjusted HR 0.65†
(0.45-0.95)
MarketScan/Clinformatics16
(dose not speciﬁed)
68 y Mean 5 mo PSM HR 0.75 (0.65-0.87) HR 0.31 (0.17-0.54) HR 0.97 (0.79-1.18) HR 0.89 (0.57-1.38)
Danish Registry of Medicinal
Product Statistics17
(150 mg)
71 y Median 10.5 mo‡ PSM HR 0.66 (0.36-1.14) HR 0.08 (0.01; 0.40) HR 1.12 (0.67-1.83) HR 0.40 (0.21-0.70)
Rivaroxaban 20 mg QD
ROCKET AF6,* Median 73 y Median 707 d Cox proportional-
hazards models
HR 1.04 (0.90-1.20) HR 0.67 (0.47-0.93) RR 1.46 P < .001k HR 0.81 (0.63-1.06)
U.S. Department
of Defense18,§
78 y Total 455 d None IR 2.86 (2.61-3.13) IR 0.22 (0.15-0.30) IR 2.53 (2.30-2.78) NR
Post-Marketing Safety
Surveillance (U.S.
Department of
Defense)19,§
78 y Total 2 y None IR 2.89 (2.71-3.08)§ Incidence 0.2%
(79 of 39,052)
Incidence 2.2%
(846 of 39,052)
NR
Apixaban 5 mg BID
ARISTOTLE7,* Median 70 y Median 1.8 y Cox proportional-
hazards models
HR 0.69 (0.60-0.80) HR 0.42 (0.30-0.58) HR 0.89 (0.70-1.15) HR 0.88 (0.66-1.17)
Humedica20 NR Total 180 d Cox proportional-
hazards models
HR 0.75 (0.63-0.88) NR NR NR
ARISTOTLE ¼ Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation; BID ¼ twice daily; CI ¼ conﬁdence interval; GI ¼ gastrointestinal; HR ¼ hazard ratio; IR ¼ incidence
rate per 100 person-years; MVA ¼ multivariate analysis; NR ¼ not reported; NVAF ¼ nonvalvular atrial ﬁbrillation; PSM ¼ propensity score matched; QD ¼ every day; RCT ¼ randomized controlled trial; RE-LY ¼
Randomized Evaluation of Long-term anticoagulation therapY; ROCKET AF¼ Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial
in Atrial Fibrillation; RR ¼ relative risk; SPAF ¼ stroke prevention in atrial ﬁbrillation.
*These studies are phase 3 RCTs in patients with NVAF.
†Following propensity score matching, the unadjusted and adjusted hazard ratios were almost all identical. For secondary bleeding end points, unadjusted hazard ratios were reported.
‡Median follow-up includes 110-mg and 150-mg patients.
§No warfarin group.
kRR was calculated from data reported in the primary publication.6
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S44 The American Journal of Medicine, Vol 129, No 11A, November 2016studies have assessed rivaroxaban using the U.S. Depart-
ment of Defense database (Table).18,19 Tamayo et al18
performed a noncomparative pharmacovigilance study of
records for 27,467 patients with NVAF taking rivaroxaban.
They observed an incidence rate for major bleeding of 2.86
(95% CI, 2.61-3.13) per 100 person-years, and for fatal
bleeding events of 0.08 (95% CI, 0.05-0.14) per 100 person-
years. Overall, of the bleeding population, the vast majority
of bleeding events were GI (88.5%), and fatalities were
rare in this cohort. Conversely, the ICH rate was very low
(36 of 478 major bleeding cases), but 50% of all fatalities in
the study were recorded in patients with ICH. A subsequent
postmarketing assessment of 39,052 NVAF patients on
rivaroxaban conﬁrmed these ﬁndings, reporting an inci-
dence rate for major bleeding of 2.89 (95% CI, 2.71-3.08)
per 100 person-years.19 The most common site for major
bleeding was GI (87.2%). Intracranial bleeds made up
8.1% of the overall incidence. These ﬁndings show that
“real-world” routine clinical care is consistent with the
safety proﬁle observed in the Rivaroxaban Once daily oral
direct factor Xa inhibition Compared with vitamin K
antagonism for prevention of stroke and Embolism Trial in
Atrial Fibrillation (ROCKET AF).6Apixaban
To date, we have one preliminary report of “real-world” use
of apixaban in comparison with warfarin. Using records of
patients with NVAF (2038 on apixaban and 24,872 on
warfarin) from a Humedica (Boston, Mass.) medical record
database, the investigators found a higher rate of bleeds
with warfarin than with apixaban (HR 1.34; 95% CI,
1.13-1.58).20All DOACs
Recently a group of researchers presented abstracts at the
2015 European Society of Cardiology meeting from 3
observational studies comparing bleeding outcomes with
apixaban vs dabigatran, rivaroxaban, or warfarin23-25 In the
ﬁrst, using data from the MarketScan Early View health
insurance claims database, they evaluated major bleeding in
60,277 patients with NVAF (n ¼ 8785 apixaban,
n ¼ 20,963 dabigatran, and n ¼ 30,529 rivaroxaban).24
They reported that rivaroxaban increased the risk for
major bleeding (adjusted HR 1.36; 95% CI, 1.23-1.52)
compared with apixaban, while dabigatran had a risk similar
to that of apixaban for major bleeding (adjusted HR 0.99;
95% CI, 0.88-1.10). Similar ﬁndings were reported in the
other 2 abstracts concerning patients with NVAF who newly
initiated oral anticoagulant therapy.20,23 Comparing Cox
proportional-hazards model adjusted HRs for inpatient and
outpatient bleeding events, they found increased risk with
warfarin or rivaroxaban compared with apixaban (adjusted
HRs: warfarin 1.62; 95% CI, 1.20-2.18; rivaroxaban 1.70;
95% CI, 1.26-2.29), but not with dabigatran compared with
apixaban (adjusted HR 1.28; 95% CI, 0.92-1.79).In a study of patients in the Cerner Health Facts hospital
database, Deitelzweig et al25 compared rates of bleeding-
related hospitalization readmissions among those previ-
ously hospitalized for NVAF and treated with apixaban,
dabigatran, or rivaroxaban. After adjusting for baseline
differences in stroke and bleeding risks, they found
increased risk of bleeding-related 30-day hospitalizations
with rivaroxaban vs apixaban (OR 1.6; P ¼ .04) but no
differences with dabigatran vs apixaban (OR 1.3; P ¼ .30).
Analyses of all-cause hospitalization, length of all-cause
hospital stay, and costs related to all-cause hospitalization
also showed apixaban to be better than rivaroxaban and
comparable to dabigatran.DISCUSSION
Randomized and controlled clinical trials with DOACs
established their efﬁcacy and safety, and provided the basis
for FDA approval for the prevention of stroke and systemic
embolism in patients with NVAF and for the prevention or
treatment of VTE. In the years since these drugs became
available to health-care providers and their patients, obser-
vational studies with data involving more than 250,000
patients have provided additional information on safety end
points, particularly bleeding—an adverse effect of all anti-
coagulation agents.
The primary advantage of postmarketing surveillance is
that it provides information not available in RCTs.
Randomized trials generally represent a small segment of
the overall population, one that is selected based on precise
entry and exclusion criteria. These trials are performed in a
cohort that excludes patients likely to be noncompliant, the
terminally ill, and those with advanced age or suffering
multiple comorbidities. Furthermore, PMSS analyses allow
the evaluation of physician bias in selecting the intervention
population. As physicians commonly opt to treat only the
lowest-risk patients when there are perceived therapeutic
risks, the PMSS study methodology thus allows the evalu-
ation of any potential alterations in a drug’s risk-to-beneﬁt
relationship that may occur as a result.
The primary limitation of all PMSS is their retrospective
nature and their (typically) relatively short duration of
follow-up when considering the currently available data
involving DOACs. The currently available PMSS are
limited in that efﬁcacy and safety outcomes have been
evaluated over mean follow-up durations of <1 year and are
not designed to select comparable groups at treatment onset.
Warfarin patients, for example, may have substantial clinical
and demographic differences in comparison with patients
treated with the DOACs. Sophisticated statistical modeling
techniques can attempt to adjust for baseline differences in
order to (hopefully) approximate the effects of randomiza-
tion in cohort preparation, but the risk of residual con-
founding always persists. The strength of PMSS data is that
they are based on large cohorts using well-established
coding extraction methods from reliable data sources.
They constitute evidence from “real-world” prescribing and
Villines and Peacock Safety of Direct Oral Anticoagulants S45use, and they may be performed independently of the drug
makers (eg, the FDA dabigatran Medicare study1). As such,
PMSS data function as a “real-world” effectiveness trans-
lation of the efﬁcacy and safety results of RCTs.
Findings from PMSS with DOACs have, in general,
supported the ﬁndings of the phase 3 clinical trials that
provided evidence of their efﬁcacy and tolerability for reg-
ulatory agencies.5-7 The potential for uncontrolled bleeding
has long been a concern with warfarin (especially when
taken with certain drugs or food),26 and similar concerns
arose at the onset of the availability of the ﬁrst DOAC,
dabigatran. However, surveillance of the FAERS database
demonstrated no differences in reported bleeding during the
ﬁrst year of availability of dabigatran.22 That assurance was
borne out in the Medicare and Department of Defense
studies that conﬁrmed the initial safety evidence of dabi-
gatran in the RE-LY trial.1,5,15,27 More recently, additional
PMSS have provided clariﬁcation of bleeding risks for
rivaroxaban and apixaban. Pharmacovigilance studies with
rivaroxaban found similar rates of bleeding to the FDA
registration ROCKET AF trial. Importantly, these studies
conﬁrmed that the vast majority of major bleeding with
rivaroxaban was GI rather than intracranial in location.
Recently, PMSS data comparing apixaban with warfarin or
other DOACs have provided further insights.
An interim analysis of the GLORIA-AF patient registry
has shown that the introduction of DOACs has inﬂuenced
patient treatment patterns, with a substantial increase in
appropriate anticoagulation among patients compared with a
prior evaluation.8 The GLORIA-AF (N ¼ 56,000) data show
that DOACs are already more commonly prescribed than
warfarin in newly diagnosed patients with NVAF. In North
America in 2015, overall OAC use was distributed as fol-
lows: VKA 26.1%, dabigatran 25%, rivaroxaban 20.5%, and
apixaban 6.6%. When all DOACs are grouped, they repre-
sent more than half of all antithrombotic prescriptions—
including antiplatelet agents or aspirin.
Investigators researching the GARFIELD registry data-
base (N ¼ 17,184) recently conﬁrmed suboptimal throm-
boprophylaxis with oral anticoagulants by both female and
male patients with newly diagnosed NVAF, and observed
that perceived bleeding risk was the main reason for not
giving VKAs (female, 14.7%; male, 17.8%).28 However,
just 1.9% of either female or male patients cited a previous
bleeding incident.
In addition to GLORIA-AF, GARFIELD, and the
RE-LY AF Registry,29 thromboprophylaxis for patients with
NVAF is being prospectively evaluated in ongoing registry
studies, including the Outcomes Registry for Better
Informed Treatment of Atrial Fibrillation (ORBIT-AF)
registry study30 and the Euro Heart Survey on Atrial
Fibrillation.31 Findings from these studies will provide
enhanced information on the incorporation of DOACs into
the atrial ﬁbrillation and VTE therapeutic regimens. Robust
PMSS evaluations of DOACs used for the prevention of
VTE are also needed to further understand the safety of
these agents.CONCLUSION
Data from PMSS evaluations of DOACs provide assurance
that the risks associated with their use are manageable and in
line with the results seen in RCTs. As expected, overall risks
for major bleeding are similar to warfarin, although the
risk for intracranial hemorrhage is signiﬁcantly reduced,
and risk for GI hemorrhage slightly increased. While all
instances of major bleeding are a concern, oral anti-
coagulation therapy is aimed at preventing potentially
debilitating or fatal thromboembolic events. The risks of
bleeding must be balanced against the beneﬁts of reduced
risk for stroke or venous thromboembolism.References
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